Kidney Int 1989; 36: 272 279. 418. Houlihan CA, Allen TJ, Baxter AL et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 2002; 25: 663 671. 419. Buter H, Hemmelder MH, Navis G et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13: 1682 1685. 420. Burgess E, Muirhead N, Rene de Cotret P et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20: 893 900. 421. Shiigai T, Shichiri M. Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001; 37: 477 483. 422. Lemarie CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010; 11: 19 31. 423. Kunz R, Friedrich C, Wolbers M et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30 48. 424. Navaneethan SD, Nigwekar SU, Sehgal AR et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 542 551. 425. Lambers Heerspink HJ, de Zeeuw D. ONTARGET still OFF-TARGET? Circulation 2011; 123: 1049 1051. 426. Parving HH, Brenner BM, McMurray JJ et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13: 387 393. 427. Novartis. Novartis announces termination of ALTITUDE study with Rasilezs/Tekturnas in high-risk patients with diabetes and renal impairment. http://www.novartis.com/newsroom/media-releases/en/ 2011/1572562.shtml (accessed on 20 December 2011). 428. 